US Patent Issued to Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute on Sept. 29 for "CD40 binding molecules and uses thereof" (New York, New Jersey Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,299, issued on Sept. 29, was assigned to Memorial Sloan Kettering Cancer Center (New York) and Tri-Institutional Therapeutics Discovery Institute Inc. (New York).

"CD40 binding molecules and uses thereof" was invented by Danny Nejad Khalil (New York), Taha Merghoub (Jersey City, N.J.), Jedd D. Wolchok (New York), Isabell Schulze (New York) and Ivo C. Lorenz (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides various CD40 binding molecules (including, but not limited to, antibodies), compositions comprising such CD40 binding molecules, and methods of using such CD40 binding molecules and compositions, for example ...